Elon Musk explains how Tesla owners will make money from its Cybercab fleet:
“For the fleet that is owned by our customers, it’ll be like an Airbnb thing. You can add or subtract your car to the fleet whenever you want.
You can say, ‘I’m going away for a week.’ Just one tap on your Tesla app, your car gets added to the fleet, and it just makes money for you while you’re gone. You can add it to the fleet for a few hours, a few days, or a few weeks.
Whenever you want it back, you can say, ‘Come back,’ and the car will come right back. I’m highly confident that the revenue made by the owner of the car will far exceed the actual monthly payment.”
We just crossed a line in medicine that humanity has been walking toward for a hundred years.
For the first time, doctors can take a biopsy of your specific tumor, read its unique DNA mutations — the exact fingerprint no other cancer on earth shares — and build a custom mRNA blueprint written for one human being. Yours.
It doesn't poison the cancer. It teaches your own immune system what to hunt.
And this week, Phase 3 results confirmed it works.
Added to the best immunotherapy we already had, this individualized cancer vaccine has been dramatically cutting the odds that high-risk melanoma comes back. In the earlier data, the combination reduced the risk of recurrence or death by 49%, and the risk of the cancer spreading to distant organs by 62%, compared to the standard treatment alone. This week's Phase 3 readout confirmed the benefit holds. That is not a modest tweak. That is a different trajectory for a human life.
And melanoma is just the first door. The same approach is now in trials across lung, bladder, and kidney cancers — a whole program of them, racing forward.
Understand what this actually means, because it's bigger than one drug.
For all of history, we fought cancer with blunt weapons. Cut it out. Burn it with radiation. Flood the whole body with chemotherapy and hope the cancer dies before the patient suffers too much. We were swinging a hammer in the dark.
This is a blueprint. A weapon designed atom by atom for one person's disease, that turns their own body into the thing that finds and destroys it. We are watching medicine shift from managing cancer to hunting it.
I've spent my life as a physician, and I did not expect to see this so soon. We were told personalized cancer vaccines were a thirty-year dream. They are happening right now, in real patients, with real data, in our lifetime.
I don't say this lightly, and I say it as a doctor who knows exactly how rare these moments are: this is one of the most hopeful things to happen in the history of the field.
I woke up thinking of the words of the morning prayer — Modeh Ani — I thank You. Gratitude, the moment you open your eyes, for a soul returned and a day given. To be alive at the exact hour when human beings learned to teach the body to cure itself feels like standing inside that prayer.
We are not at the end of cancer. But we are, unmistakably, at the beginning of the end of its reign.
The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer https://t.co/cv4iXW11mw
Why this is a big deal:
this mRNA therapy instructs the body to produce the specific fingerprints of the person's tumor and trains the immune system to hunt and kill it.
First time in a Phase 3 trial.
One way cancer grows is by hiding from the immune system and turning off attacking T-cells. This mRNA therapy provides the tumor's genetic fingerprint so that the immune system can train T-cells to identify the cancer. Keytruda then removes the brakes that cancer had put on the T-cells enabling them to eliminate the cancer.
Moderna just became the first company in history to pass a Phase 3 trial with a personalized cancer vaccine. Every single dose is a different drug.
Here's how it works. Surgeons remove the melanoma, then sequence the tumor's DNA and RNA. An algorithm compares it against the patient's healthy cells and picks up to 34 mutations unique to that one person's cancer.
Those mutations get encoded into a custom mRNA strand, wrapped in lipid nanoparticles, and injected. The immune system reads the code, learns what that specific tumor looks like, and hunts down whatever cells surgery missed. Paired with Keytruda, which releases the brakes on T cells, the earlier trial showed a 49% cut in recurrence risk that held steady from year 3 all the way to year 5.
The manufacturing is what pharma people can't stop thinking about.
Drug factories are built to stamp out identical pills by the billion. This requires designing, synthesizing, and quality-testing a brand new drug for every patient, in weeks, from biopsy to injection. A batch size of one.
Scientists have chased therapeutic cancer vaccines for 40 years. A handful got approved. None were mRNA, and none were built per patient.
The Phase 3 covered 1,137 melanoma patients. Nine more trials are already running in lung, bladder, kidney, pancreatic, and gastric cancer.
Moderna was worth $25 billion yesterday, down more than 85% from its COVID peak. Wall Street had priced mRNA as a one-pandemic technology. The repricing took one morning.
73% of ALL $SPCX shares in existence are now in the hands of known whales , companies, nations and basically wealthy people who don’t need money and will hold forever.
There is only 27% remaining that can be sold… BUT a large part of this 27% are held by retail and the musk cult who will also NEVER sell.
So its very likely that demand > supply forever
@elonmusk > owns 48.4 % of spacex
Google > 4.2%
Antonio Gracias > 3.8%
Peter Thiel > 3.2%
Fidelity > 2.3%
Gigafund > 1.3%
Saudi Arabia > 1.2%
Ron Baron > 1.1%
Nvidia> 1%
Sequoia > 1%
Do with this info what you will
🚨 SHOCKING: LISA SU’S $1,499 LUNCHBOX ANNIHILATES NVIDIA’S $4K AI BEAST!
AMD CEO Lisa Su walked on stage, held a lunchbox sized PC in one hand, and ran a 235 billion parameter model live.
No data center. No cloud. No rented GPU.
The chip inside is the AMD Ryzen AI Max+ 395. It is the first x86 chip where the CPU and GPU share the same pool of memory. Up to 128GB of unified memory. That one design choice is what changes everything.
An RTX 5090 gives you 32GB of video memory. A 4090 gives you 24. This box gives you more than three times either of them in a chassis you can carry in a backpack.
On DeepSeek R1 inference, AMD's chip beat an Nvidia RTX 5080 by more than 3x. A desktop the size of a thick paperback outrunning a dedicated graphics card that costs over a thousand dollars on a real AI workload.
Now do the math on your subscriptions.
Claude Code Max is $200 a month. ChatGPT Pro is another $200. Cursor is $20. Gemini is $20. That is $5,280 leaving your account every year before you build a single thing.
The 128GB version of this machine starts at around $2,399. At that run rate it pays for itself in under a year and then runs free.
Install Ollama. Pull Qwen3 235B. Point Claude Code at localhost. Same interface you already use. Nothing leaves your machine. Nothing costs per request. No throttling at 3am when you finally have time to build.
Lawyers stop worrying about what OpenAI does with their files. Developers stop watching the token counter. Founders stop killing prototypes because the cloud bill scared them off.
Private AI just became something a normal person can own.
BREAKING: Elon Musk has become the world's first trillionaire.
After SpaceX raised a record $75 billion in its IPO, Musk’s net worth shot up to top $1.1 trillion when the stock began trading Friday, putting him in an economic class of his own.
Combined with his holdings in electric vehicle maker Tesla, as well as other investments and assets, Musk's net worth is now estimated at about $1.1 trillion.
Musk's stake in the rocket and satellite company alone is now estimated at a staggering $690 billion, but it's also a life-changing moment for thousands of workers at the company who hold equity.
Investors who watched Musk help turn Tesla into an automotive giant are now betting he can do the same in space and artificial intelligence, as SpaceX launches the largest IPO in history.